Badri Modi, M.D.
"Dermatologists play an important role in the primary and supportive care of cancer patients."
As a dermatologist working at City of Hope, Badri Modi, M.D. focuses on identification and management of high risk skin cancers such as melanoma. Furthermore, he cares for patients with cutaneous complications from the treatment of internal malignancies like leukemia and breast cancer, which can be as or more devastating than the underlying disease.
Dr. Modi received his medical degree from Yale University, completed an internship in internal medicine at The Massachusetts General Hospital and completed dermatology residency at the University of Pennsylvania, where he served as chief resident in his final year. He has published numerous peer-reviewed articles related to cancer research and clinical care.
Dr. Modi finds fulfillment in using his knowledge and skills to help others, especially in difficult cases. He chose City of Hope “to work with patients with challenging cancers.”
2012, M.D., Yale University School of Medicine
2007, B.S., Emory University
2010-2011, Research Fellow, Laboratory of Michael Girardi, New Haven, CT
2013-2016, Resident in Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
2012-2013, Intern in Medicine, Massachusetts General Hospital, Boston, MA
2015, Resident International Grant, American Academy of Dermatology
2015, Medical Student Teaching Award Winner, Edward E. Bondi Dermatologic Society, University of Pennsylvania
2013, Centers of Expertise in Global & Humanitarian Health Travel Grant, Massachusetts General Hospital
2012, William Gardner Prize for Most Outstanding Thesis, Yale University School of Medicine
2011, Richard K. Gershon Student Research Fellowship, Yale University School of Medicine
2007, Phi Beta Kappa, Emory University
2007, President of the Year, for role as President of the Indian Cultural Exchange, Emory University
- Armenian SH, Lindenfeld L, Iukuridze A, Echevarria M, Bebel S, Coleman C, Nakamura R, Abdullah F, Modi B, Oeffinger KC, Emmons KM, Marghoob AA, Geller AC. Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers (TEACH). BMC Cancer. 2020 Aug 3;20(1):721. doi: 10.1186/s12885-020-07232-2. PMID: 32746799.
- Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Ulrich C, Eigentler T, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary Analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 Jun;8(1):e000775. doi: 10.1136//jitc-2020-000775. PMID: 32554615
- Ali H, Salhotra A, Modi B, Nakamura R. Ruxolitinib for the treatment of graft-versus-host disease. Expert Rev Clin Immunol. 2020 Apr;16(4):347-359. doi: 10.1080/1744666X.2020.1740592. Epub 2020 Apr 1. PMID: 32153201
- Virgen CA, Nguyen TA, Di Raimondo C, Amini A, Margolin KA, Parekh V, Abdulla FR, Modi B. Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2020 Feb 19:6(3):195-197. doi: 10.1016/j.jdcr.2020.01.008. eCollection 2020 Mar. PMID: 32149176
- Shinde A, Verma V, Jones BL, Li R, Glaser S, Freeman M, Melstrom L, Kang R, Parvathaneni U, Modi B, Amini A. The Effect of Time to Postoperative Radiation Therapy on Survival in Resected Merkel Cell Carcinoma. Am J Clin Oncol 2019 Aug;42(8):636-642. doi: 10.1097/COC.0000000000000565. PMID: 31246585
- Migden M, Rischin D, Schmults C, Guminski A, Hauschild A, Lewis K, Chung C, Hernandez-Aya L, Lim A, Chang A, Rabinowits G, Thai A, Dunn L, Hughes B, Khusalani N, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker H, Brana I, Gil-Martin M, Homsi J, Johnson M, Moreno V, Niu Jiaxin, Owonikoko T, Papadopoulos K, Yancopoulos G, Lowry I, Fury M. PD-1 blockade with Cemiplimab in advanced cutaneous squamous cell carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4. PMID: 29863979. Impact Factor: 72.406
- Modi B, Hernandez-Henderson M, Yang D, Klein J, Dadwal S, Kopp E, Huelsman K, Mokhtari S, Ali H, Malki MMA, Spielberger R, Salhotra A, Parker P, Forman S, Nakamura R. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2019 Feb;25(2):265-269. doi: 10.1016/j.bbmt.2018.09.003. Epub 2018 Sep 8. PMID: 30201397
- Ghosh K, Modi B, James WD, Capell BC. BAP1: Case Report and Insight into a Novel Tumor Suppressor. BMC Dermatol. 2017 Nov 22; 17(1):13. doi: 10.1186/s12895-017-0065-63. PMID: 29166932
- Sobanko JF, Da Silva D, Chiesa Fuxench ZC, Modi B, Shin TM, Etzkorn JR,Samimi SS, Wanat KA, Miller CJ. Preoperative telephone consultation does not decrease patient anxiety before Mohs micrographic surgery. J Am Acad Dermatol. 2017 March;76(3): 519-526. doi: 10.1016/j.jaad.2016.08.027. PMID: 27923500. Impact factor 4.449
- Tracey E, Modi B, Micheletti R. Pemetrexed-induced pseudocellulitis reaction with eosinophilic infiltrate on skin biopsy. Am J Dermatopathol. 2017 Jan; 39(1):e1-e2. doi:10.1097/DAD.000000000000645. PMID: 27415636. Impact factor: 1.426